Tompkins Financial Corp Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Tompkins Financial Corp grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 16.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,374 shares of the company's stock after buying an additional 5,177 shares during the quarter. Tompkins Financial Corp's holdings in Johnson & Johnson were worth $5,405,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. State Street Corp raised its stake in shares of Johnson & Johnson by 0.9% during the third quarter. State Street Corp now owns 134,245,811 shares of the company's stock valued at $21,755,874,000 after acquiring an additional 1,154,088 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company's stock worth $9,064,149,000 after buying an additional 1,004,763 shares during the period. FMR LLC increased its stake in shares of Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company's stock valued at $2,968,440,000 after buying an additional 1,265,748 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Royal Bank of Canada upped their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Bank of America lowered their price target on shares of Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday. Finally, StockNews.com downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE JNJ traded down $0.74 during trading on Friday, hitting $147.03. 10,678,393 shares of the company were exchanged, compared to its average volume of 6,880,262. The company has a fifty day moving average price of $148.51 and a 200-day moving average price of $156.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $353.99 billion, a PE ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.